News Releases Keyword search Year None202220212020201920182017201620152014201320122011201020092008 9/6/2022 AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference 8/25/2022 AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting 8/11/2022 AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update 8/11/2022 AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 8/10/2022 AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting 7/28/2022 AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022 5/20/2022 AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference 5/19/2022 AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® 5/16/2022 AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update 5/10/2022 AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia Current page 1 Page 2 Page 3 Next page next › Last page last » Print Page RSS Feeds
Keyword search Year None202220212020201920182017201620152014201320122011201020092008 9/6/2022 AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference 8/25/2022 AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting 8/11/2022 AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update 8/11/2022 AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 8/10/2022 AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting 7/28/2022 AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022 5/20/2022 AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference 5/19/2022 AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® 5/16/2022 AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update 5/10/2022 AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia Current page 1 Page 2 Page 3 Next page next › Last page last »
8/25/2022 AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
8/11/2022 AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/11/2022 AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022
8/10/2022 AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
5/16/2022 AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022 AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia
